reports
- Jean-François Granjon
VAC PIERRE & VACANCES SA
EVT EVOTEC SE
IDL ID LOGISTICS GROUP
EXE EXEL INDUSTRIES SA
POM PLASTIC OMNIUM SE
WHA WERELDHAVE N.V.
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
ALCAR CARMAT SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BB SOCIETE BIC SA
NEX NEXANS SA
CTAC CTAC N.V.
ROYAL VOPAK NV
MMT METROPOLE TELEVISION SA
SEFER SERGEFERRARI GROUP SA
SHOT SCANDIC HOTELS GROUP
MELE MELEXIS NV
ALVDM VOYAGEURS DU MONDE SA
TKO TIKEHAU CAPITAL SCA
ALKAL KALRAY SA
DSC1 DUTCH STAR C SHAR
ZEL PHARMA MAR SA
BAR BARCO NV
OVH OVH GROUPE
FORSE FORSEE POWER SA
SPM SAIPEM S.P.A.
- Jean-François Granjon
VAC PIERRE & VACANCES SA
EVT EVOTEC SE
IDL ID LOGISTICS GROUP
EXE EXEL INDUSTRIES SA
POM PLASTIC OMNIUM SE
WHA WERELDHAVE N.V.
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
ALCAR CARMAT SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BB SOCIETE BIC SA
NEX NEXANS SA
CTAC CTAC N.V.
ROYAL VOPAK NV
MMT METROPOLE TELEVISION SA
SEFER SERGEFERRARI GROUP SA
SHOT SCANDIC HOTELS GROUP
MELE MELEXIS NV
ALVDM VOYAGEURS DU MONDE SA
TKO TIKEHAU CAPITAL SCA
ALKAL KALRAY SA
DSC1 DUTCH STAR C SHAR
ZEL PHARMA MAR SA
BAR BARCO NV
OVH OVH GROUPE
FORSE FORSEE POWER SA
SPM SAIPEM S.P.A.
- Juan Ros-Padilla
Pharma Mar : Q1 earnings in line
>Oncology gains momentum - Sales grew +12% y-o-y in Q1 2024 (vs -20% in Q4 and -9% in Q3). Biopharma sales increased +25% y-o-y in Q1 2024 (compared to -32% in Q4 and -27% in Q3) namely owing to higher revenues from Zepzelca and, to a lesser extent, also higher raw material and ‘early access’ sales. Royalties posted a +14% y-o-y increase (vs -6% in Q4 and+20% in Q3) while the more erratic licence revenues declined -8% which nonetheless implies a material sequential im...
- Charlotte Vaisse
- Jean-Baptiste Rouphael
- Luis de Toledo Heras
AMS AMS AG
CO CASINO GUICHARD-PERRACHON SA
ATO ATOS SE
GTT GAZTRANSPORT & TECHNIGAZ SA
NXI NEXITY SA CLASS A
SBMO SBM OFFSHORE NV
MF WENDEL SE
KORI KORIAN SA
ITP INTERPARFUMS
G24 SCOUT24 AG
GLB GLANBIA PLC
VRNL VERNEUIL PARTICIPATIONS
SOC SUBSEA 7 S.A.
VID VIDRALA SA
AIXA AIXTRON SE
PAT PATRIZIA AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
FNTN FREENET AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
IDR INDRA SISTEMAS S.A. CLASS A
SMCP SMCP SA
BFSA BEFESA SA
S92 SMA SOLAR TECHNOLOGY AG
NEOEN NEOEN S.A.
GRE GRENERGY RENOVABLES
THEP THERMADOR HOLDING SA
DSC1 DUTCH STAR C SHAR
ZEL PHARMA MAR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
SOL SOLTEC POWER HOLDINGS
TE TECHNIP ENERGIES NV
FUR FUGRO NV
EXN EXCLUSIVE NETWORKS SA
ALLFG ALLFUNDS (UK) LTD
EAPI EUROAPI
SPM SAIPEM S.P.A.
AF AIR FRANCE - KLM
SCHOTT PHARMA AG
- Charlotte Vaisse
- Jean-Baptiste Rouphael
- Luis de Toledo Heras
BMW BAYERISCHE MOTOREN WERKE AG
AMS AMS AG
CO CASINO GUICHARD-PERRACHON SA
RNO RENAULT SA
ATO ATOS SE
GTT GAZTRANSPORT & TECHNIGAZ SA
NXI NEXITY SA CLASS A
DAI DAIMLER AG
SBMO SBM OFFSHORE NV
MF WENDEL SE
KORI KORIAN SA
ITP INTERPARFUMS
G24 SCOUT24 AG
VOW3 VOLKSWAGEN AG PREF
GLB GLANBIA PLC
VRNL VERNEUIL PARTICIPATIONS
SOC SUBSEA 7 S.A.
VID VIDRALA SA
AIXA AIXTRON SE
PAT PATRIZIA AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
FNTN FREENET AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
IDR INDRA SISTEMAS S.A. CLASS A
SMCP SMCP SA
BFSA BEFESA SA
S92 SMA SOLAR TECHNOLOGY AG
NEOEN NEOEN S.A.
GRE GRENERGY RENOVABLES
THEP THERMADOR HOLDING SA
DSC1 DUTCH STAR C SHAR
ZEL PHARMA MAR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
SOL SOLTEC POWER HOLDINGS
STLA STELLANTIS N.V.
TE TECHNIP ENERGIES NV
FUR FUGRO NV
EXN EXCLUSIVE NETWORKS SA
ALLFG ALLFUNDS (UK) LTD
EAPI EUROAPI
SPM SAIPEM S.P.A.
AF AIR FRANCE - KLM
SCHOTT PHARMA AG
- Juan Ros-Padilla
Pharma Mar : Q4 EBITDA and bottom line somewhat better albeit negative
>Higher royalties offset the anticipated oncology slowdown - Total revenues receded significantly -20% y-o-y in Q4 2023 (vs -9% in Q3 and -1% in Q2), yet they were above our estimate helped by higher-than-expected royalties and licences (€ 29m vs € 20m est.). Biopharma sales decreased -32% y-o-y in Q4 2023 (compared to -27% in Q3 and -2% in Q2) reflecting a normalisation after the inflated figures seen in previous quarters that were favoured by one-off ‘early-access...
- Anthony Dick
- Michael Foundoukidis
PROX PROXIMUS SA DE DROIT PUBLIC
ATO ATOS SE
MF WENDEL SE
TFI TELEVISION FRANCAISE 1 SA
SBS STRATEC SE
POM PLASTIC OMNIUM SE
STF STEF
ASY ASSYSTEM SA
CGM CEGEDIM SA
VETO VETOQUINOL SA
MTU MANITOU BF SA
FII LISI SA
FNAC FNAC DARTY SA
ATE ALTEN SA
FR VALEO SE
ELIS ELIS SA
AF AIR FRANCE-KLM SA
FAE FAES FARMA S.A.
COFB COFINIMMO SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
TIETO TIETOEVRY OYJ
SESL SES-IMAGOTAG SA
MONT MONTEA SCA
SIGHT GENSIGHT BIOLOGICS SA
ONTEX ONTEX GROUP N.V.
LIGHT SIGNIFY NV
XIL XILAM ANIMATION SA
GCO GRUPO CATALANA OCCIDENTE S.A.
TEC TECHNIPFMC PLC
XFAB X-FAB SILICON FOUNDRIES SE
BFSA BEFESA SA
VOS VOSSLOH AG
SAB BANCO DE SABADELL SA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
FPE3 FUCHS PETROLUB SE
SPM SAIPEM S.P.A.
- Anthony Dick
- Michael Foundoukidis
PROX PROXIMUS SA DE DROIT PUBLIC
ATO ATOS SE
MF WENDEL SE
TFI TELEVISION FRANCAISE 1 SA
SBS STRATEC SE
POM PLASTIC OMNIUM SE
STF STEF
ASY ASSYSTEM SA
CGM CEGEDIM SA
VETO VETOQUINOL SA
MTU MANITOU BF SA
FII LISI SA
FNAC FNAC DARTY SA
ATE ALTEN SA
FR VALEO SE
ELIS ELIS SA
AF AIR FRANCE-KLM SA
FAE FAES FARMA S.A.
COFB COFINIMMO SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
TIETO TIETOEVRY OYJ
SESL SES-IMAGOTAG SA
MONT MONTEA SCA
SIGHT GENSIGHT BIOLOGICS SA
ONTEX ONTEX GROUP N.V.
LIGHT SIGNIFY NV
XIL XILAM ANIMATION SA
GCO GRUPO CATALANA OCCIDENTE S.A.
TEC TECHNIPFMC PLC
XFAB X-FAB SILICON FOUNDRIES SE
BFSA BEFESA SA
VOS VOSSLOH AG
SAB BANCO DE SABADELL SA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
FPE3 FUCHS PETROLUB SE
SPM SAIPEM S.P.A.
- Juan Ros-Padilla
Pharma Mar : Q3 earnings above on higher-than-expected royalties
>Higher royalties offset the anticipated oncology slowdown - Total revenues receded -9% y-o-y in Q3 2023 (vs -1% in Q2 2023). This figure, however, is 24% above our estimate, driven by significantly higher royalties (€ 17m vs. € 10m in Q2 and € 7m estimated for Q3). Biopharma sales decreased 27% y-o-y in Q3 2023 (vs -2% in Q2 2023) reflecting a normalisation after the inflated figures seen in previous quarters that were favoured by one-off ‘early-access’ adjustments i...
- Jean-François Granjon
ODDO BHF Small & MIDCAP MORNING NEWS - 25/10/2023 Date Performance dep...
En amont des publications T3, nous sommes confiants pour le secteur, qui devrait confirmer le scenario de soft landing, ce qui limite les risques de warning. Toutefois, nous redoutons la réaction du marché alors que les commentaires devraient indiquer une poursuite du ralentissement au T4 menant à des croissances embarquées faibles début 2024. Ceci nous conduit à abaisser nos prévisions de croissance de plusieurs titres et limite le momentum du secteur. Dans ce contexte, nos top picks...
LHA DEUTSCHE LUFTHANSA AG
SOP SOPRA STERIA GROUP SA
GTT GAZTRANSPORT & TECHNIGAZ SA
IDL ID LOGISTICS GROUP
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
PIG HAULOTTE GROUP SA
GOE GROUPE GORGE SA
CDA COMPAGNIE DES ALPES SA
WIZZ WIZZ AIR HOLDINGS PLC
NEX NEXANS SA
EZJ EASYJET PLC
AF AIR FRANCE-KLM SA
RY4C RYANAIR HOLDINGS PLC
MAREL MAREL HF.
ROYAL VOPAK NV
ALVIV VISIATIV SA
MELE MELEXIS NV
DR0 DEUTSCHE ROHSTOFF AG
MVC METROVACESA SA
ZEL PHARMA MAR SA
BLV BELIEVE SA
OVH OVH GROUPE
- Jean-François Granjon
ODDO BHF Small & MIDCAP MORNING NEWS - 10/25/2023 Date Performance sin...
Ahead of the Q3 publications, we are confident on the sector, which should confirm a soft-landing scenario which limits risks of a warning. However, we fear the market’s reaction as comments are likely to indicate a continuing slowdown in Q4, resulting in weak embedded growth in early 2024. This leads us to lower our growth forecasts for several companies and limits sector momentum. In this context, our Top Picks are: Sopra Steria, Indra, Alten, Bechtle, Wavestone and Assystem. - ...
SOP SOPRA STERIA GROUP SA
GTT GAZTRANSPORT & TECHNIGAZ SA
IDL ID LOGISTICS GROUP
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
PIG HAULOTTE GROUP SA
GOE GROUPE GORGE SA
CDA COMPAGNIE DES ALPES SA
NEX NEXANS SA
MAREL MAREL HF.
ROYAL VOPAK NV
ALVIV VISIATIV SA
MELE MELEXIS NV
DR0 DEUTSCHE ROHSTOFF AG
MVC METROVACESA SA
ZEL PHARMA MAR SA
BLV BELIEVE SA
OVH OVH GROUPE
- Juan Ros-Padilla
Pharma Mar : Q3 preview: oncology sales to normalize after the Q2 ‘ear...
>Oncology revenues normalise and return to the levels seen in Q1 2023/Q4 2022 - Q3 2023 results will be released next 26 October. We expect total revenue to decrease by 27% y-o-y to € 30m explained by lower royalties (-50% y-o-y to € 7m), lower licences (-19% to € 6m) and the normalisation of the oncology revenues (-21% to € 17m vs the € 28m seen in Q2 that were inflated by the one-off ‘early-access’ adjustment in Lurbinectedin. At the EBITDA level, we expect a slight...
- Anthony Dick
- Gautier Le Bihan
- Michael Foundoukidis
PROX PROXIMUS SA DE DROIT PUBLIC
BEKB BEKAERT SA
SOP SOPRA STERIA GROUP SA
APAML APERAM SA
EO FAURECIA SA
GTT GAZTRANSPORT & TECHNIGAZ SA
MF WENDEL SE
TFI TELEVISION FRANCAISE 1 SA
KORI KORIAN SA
ALCLA CLASQUIN SA
CGM CEGEDIM SA
NTG NETGEM SA
EKI EKINOPS SA
NRG NRJ GROUP SA
MRN MERSEN SA
MTU MANITOU BF SA
LSS LECTRA SA
FNAC FNAC DARTY SA
ALTA ALTAREA SCA
ATE ALTEN SA
FR VALEO SE
AF AIR FRANCE-KLM SA
ICAD ICADE SA
COFB COFINIMMO SA
BRE BREMBO S.P.A.
MBWS MARIE BRIZARD WINE & SPIRITS SA
CTAC CTAC N.V.
AIXA AIXTRON SE
VIS VISCOFAN S.A.
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
ROYAL VOPAK NV
SESL SES-IMAGOTAG SA
PAT PATRIZIA AG
MCPHY MCPHY ENERGY SA
BRNL BRUNEL INTERNATIONAL N.V.
ONTEX ONTEX GROUP N.V.
WAF SILTRONIC AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
COL INMOBILIARIA COLONIAL SOCIMI SA
TLGO TALGO SA
IDR INDRA SISTEMAS S.A. CLASS A
TEC TECHNIPFMC PLC
TKO TIKEHAU CAPITAL SCA
XFAB X-FAB SILICON FOUNDRIES SE
UNI UNICAJA BANCO S.A.
SMCP SMCP SA
CGG CGG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
NEOEN NEOEN S.A.
THEP THERMADOR HOLDING SA
TITC TITAN CEMENT INTERNATIONAL N.V.
HAG HENSOLDT AG
VK VALLOUREC SA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
TE TECHNIP ENERGIES NV
ALHRS HYDROGEN REFUELING SOLUTIONS
FPE3 FUCHS PETROLUB SE
FUR FUGRO NV
ALLFG ALLFUNDS (UK) LTD
SPM SAIPEM S.P.A.
FLOW FLOW TRADERS LTD
- Anthony Dick
- Gautier Le Bihan
- Michael Foundoukidis
PROX PROXIMUS SA DE DROIT PUBLIC
BEKB BEKAERT SA
SOP SOPRA STERIA GROUP SA
APAML APERAM SA
EO FAURECIA SA
GTT GAZTRANSPORT & TECHNIGAZ SA
MF WENDEL SE
TFI TELEVISION FRANCAISE 1 SA
KORI KORIAN SA
ALCLA CLASQUIN SA
CGM CEGEDIM SA
NTG NETGEM SA
EKI EKINOPS SA
NRG NRJ GROUP SA
MRN MERSEN SA
MTU MANITOU BF SA
LSS LECTRA SA
FNAC FNAC DARTY SA
ALTA ALTAREA SCA
ATE ALTEN SA
FR VALEO SE
AF AIR FRANCE-KLM SA
COFB COFINIMMO SA
BRE BREMBO S.P.A.
MBWS MARIE BRIZARD WINE & SPIRITS SA
CTAC CTAC N.V.
AIXA AIXTRON SE
VIS VISCOFAN S.A.
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
ROYAL VOPAK NV
SESL SES-IMAGOTAG SA
PAT PATRIZIA AG
MCPHY MCPHY ENERGY SA
BRNL BRUNEL INTERNATIONAL N.V.
ONTEX ONTEX GROUP N.V.
WAF SILTRONIC AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
COL INMOBILIARIA COLONIAL SOCIMI SA
TLGO TALGO SA
IDR INDRA SISTEMAS S.A. CLASS A
TEC TECHNIPFMC PLC
TKO TIKEHAU CAPITAL SCA
XFAB X-FAB SILICON FOUNDRIES SE
UNI UNICAJA BANCO S.A.
SMCP SMCP SA
CGG CGG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
NEOEN NEOEN S.A.
THEP THERMADOR HOLDING SA
TITC TITAN CEMENT INTERNATIONAL N.V.
HAG HENSOLDT AG
VK VALLOUREC SA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
TE TECHNIP ENERGIES NV
ALHRS HYDROGEN REFUELING SOLUTIONS
FPE3 FUCHS PETROLUB SE
FUR FUGRO NV
ALLFG ALLFUNDS (UK) LTD
SPM SAIPEM S.P.A.
FLOW FLOW TRADERS LTD
- Juan Ros-Padilla
Pharma Mar : Q2 earnings above
>Momentum, albeit still weak, improves sequentially - Total revenues receded just -1% y-o-y in Q2 2023 (vs -60% in Q1 2023, -40% in Q4 2022 and -3% in Q3 2022) and was broadly in line with our numbers and the consensus. Biopharma sales decreased -2% y-o-y in Q2 2023 (compared to -50% in Q1 2023, -44% in Q4 2022 and -18% in Q3 2022) reflecting lower Yondelis revenues (forced price reduction after the patent cliff) and an imposed price reduction in Zepzelca’s early acc...
- Emira Sagaama
- Jean Danjou
- Oliver Metzger
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
OSE OSE IMMUNOTHERAPEUTICS SA
MF WENDEL SE
TFI TELEVISION FRANCAISE 1 SA
SBS STRATEC SE
ASY ASSYSTEM SA
CGM CEGEDIM SA
RIN VILMORIN & CIE SA
FII LISI SA
LSS LECTRA SA
GOE GROUPE GORGE SA
ALTA ALTAREA SCA
PGS PGS ASA
ACX ACERINOX SA
DEQ DEUTSCHE EUROSHOP AG
COFB COFINIMMO SA
SAVE SAVENCIA SA
FIE FIELMANN AG
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
VID VIDRALA SA
AIXA AIXTRON SE
ROYAL VOPAK NV
SESL SES-IMAGOTAG SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
RENE REDES ENERGETICAS NACIONAIS SA
SPIE SPIE SA
IBG IBERPAPEL GESTION S.A.
IDR INDRA SISTEMAS S.A. CLASS A
XFAB X-FAB SILICON FOUNDRIES SE
VOS VOSSLOH AG
SAB BANCO DE SABADELL SA
WAVE WAVESTONE SA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
ALHRS HYDROGEN REFUELING SOLUTIONS
BLV BELIEVE SA
- Juan Ros-Padilla
- Luis de Toledo Heras
Pharma Mar : Very weak Q1 earnings yet Zepzelca’s potential remains. U...
>Feeble Q1 2022 earnings yet unrelated to Zepzelca’s potential. - Total revenues receded significantly -60% y-o-y in Q1 2023 (vs -40 in Q4 2022, -3% in Q3 2022 and +2% in Q2 2022) and came notably below our numbers and the consensus. Biopharma sales decreased -50% y-o-y in Q1 2023 (compared to -44% in Q4 2022, -18% in Q3 2022 and -2% in Q2 2022) reflecting lower Yondelis revenues (forced price reduction after the patent cliff) and an imposed price reduction in Zepzel...
- Emira Sagaama
- Jean Danjou
- Oliver Metzger
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
OSE OSE IMMUNOTHERAPEUTICS SA
MF WENDEL SE
TFI TELEVISION FRANCAISE 1 SA
SBS STRATEC SE
ASY ASSYSTEM SA
CGM CEGEDIM SA
RIN VILMORIN & CIE SA
FII LISI SA
LSS LECTRA SA
GOE GROUPE GORGE SA
ALTA ALTAREA SCA
PGS PGS ASA
ACX ACERINOX SA
DEQ DEUTSCHE EUROSHOP AG
COFB COFINIMMO SA
SAVE SAVENCIA SA
FIE FIELMANN AG
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
VID VIDRALA SA
AIXA AIXTRON SE
ROYAL VOPAK NV
SESL SES-IMAGOTAG SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
RENE REDES ENERGETICAS NACIONAIS SA
SPIE SPIE SA
IBG IBERPAPEL GESTION S.A.
IDR INDRA SISTEMAS S.A. CLASS A
XFAB X-FAB SILICON FOUNDRIES SE
VOS VOSSLOH AG
SAB BANCO DE SABADELL SA
WAVE WAVESTONE SA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
ALHRS HYDROGEN REFUELING SOLUTIONS
BLV BELIEVE SA
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
1COV COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
1COV COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.